PMID- 22749337
OWN - NLM
STAT- MEDLINE
DCOM- 20121116
LR  - 20120903
IS  - 1872-8421 (Electronic)
IS  - 0165-5728 (Linking)
VI  - 251
IP  - 1-2
DP  - 2012 Oct 15
TI  - Oral treatment with laquinimod augments regulatory T-cells and brain-derived 
      neurotrophic factor expression and reduces injury in the CNS of mice with 
      experimental autoimmune encephalomyelitis.
PG  - 14-24
LID - 10.1016/j.jneuroim.2012.06.005 [doi]
AB  - Laquinimod is an orally active molecule that showed efficacy in clinical trials 
      in multiple sclerosis. We studied its effects in the CNS, when administered by 
      therapeutic regimen to mice inflicted with experimental autoimmune 
      encephalomyelitis (EAE). Laquinimod reduced clinical and inflammatory 
      manifestations and elevated the prevalence of T-regulatory cells in the brain. In 
      untreated mice, in the chronic disease stage, brain derived neurotrophic factor 
      (BDNF) expression was impaired. Laquinimod treatment restored BDNF expression to 
      its level in healthy controls. Furthermore, CNS injury, manifested by 
      astrogliosis, demyelination and axonal damages, was significantly reduced 
      following laquinimod treatment, indicating its immunomodulatory and 
      neuroprotective activity.
CI  - Copyright (c) 2012 Elsevier B.V. All rights reserved.
FAU - Aharoni, Rina
AU  - Aharoni R
AD  - Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel. 
      rina.aharoni@weizmann.ac.il
FAU - Saada, Ravit
AU  - Saada R
FAU - Eilam, Raya
AU  - Eilam R
FAU - Hayardeny, Liat
AU  - Hayardeny L
FAU - Sela, Michael
AU  - Sela M
FAU - Arnon, Ruth
AU  - Arnon R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120628
PL  - Netherlands
TA  - J Neuroimmunol
JT  - Journal of neuroimmunology
JID - 8109498
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Immunologic Factors)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Quinolones)
RN  - 908SY76S4G (laquinimod)
SB  - IM
MH  - Animals
MH  - Axons/drug effects
MH  - Brain-Derived Neurotrophic Factor/*biosynthesis
MH  - Demyelinating Diseases/drug therapy
MH  - Disease Models, Animal
MH  - Encephalomyelitis, Autoimmune, Experimental/*drug therapy/metabolism
MH  - Female
MH  - Immunologic Factors/*therapeutic use
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Multiple Sclerosis/drug therapy
MH  - Neuroprotective Agents/*therapeutic use
MH  - Quinolones/*therapeutic use
MH  - T-Lymphocytes, Regulatory/*drug effects
EDAT- 2012/07/04 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/07/04 06:00
PHST- 2012/03/27 00:00 [received]
PHST- 2012/05/22 00:00 [revised]
PHST- 2012/06/07 00:00 [accepted]
PHST- 2012/07/04 06:00 [entrez]
PHST- 2012/07/04 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - S0165-5728(12)00187-7 [pii]
AID - 10.1016/j.jneuroim.2012.06.005 [doi]
PST - ppublish
SO  - J Neuroimmunol. 2012 Oct 15;251(1-2):14-24. doi: 10.1016/j.jneuroim.2012.06.005. 
      Epub 2012 Jun 28.